Globus Medical Inc. Class A Common Stock vs US Foods Holding Corp. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while US Foods Holding Corp. Common Stock trades at $98.45 (market cap $21.18B). The key difference: US Foods Holding Corp. Common Stock is far larger — about 2.1× Globus Medical Inc. Class A Common Stock's market cap, and US Foods Holding Corp. Common Stock is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and US Foods Holding Corp. Common Stock for 6 Days on average.
| GMED | USFD | |
|---|---|---|
Market Cap | $10.25B | $21.18B |
Volume | 1,108,124 | 1,065,315 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $110.94 |
52-Week Low | $58.33 | $70.05 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $26.53B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
US Foods (USFD) trades at $97.91, showing modest daily gains of 0.21%. The stock maintains a bullish technical trend with strong moving average support and trades near key resistance at $98. Fundamentally, the company demonstrates solid revenue growth with $39.42B in 2025 sales and improving profitability, though net margins remain thin at 1.81%. Recent business developments include new product launches and conference participation, signaling ongoing operational momentum.
The outlook remains positive with analyst consensus strongly favoring Buy ratings (73%) and a $117 price target suggesting 19% upside. Key opportunities include margin expansion and market share gains, while risks involve competitive pressures and execution challenges in a low-margin industry. The combination of technical strength, fundamental improvement, and Wall Street support positions USFD favorably for continued growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →